Overview

Detailed Summary

Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company that develops, manufactures and markets generics, OTC, dermaceutics, nutraceuticals, pet-care products and mobility aids, operating both in-house plants and a network of contract manufacturing partners while supplying finished formulations to multiple international markets.
Q3 FY26 total income rose to INR160.92 crore (+57% YoY) and 9M FY26 revenue reached INR426 crore (+48% YoY); EBITDA margins expanded meaningfully to ~15–16% with Q3 EBITDA of INR26.34 crore and net profit nearly doubling, reflecting simultaneous top-line growth and operational margin improvement across Fredun Pharmaceuticals' portfolio.
The company is rapidly scaling its new-age verticals — pet care, mobility, dermaceutics and nutraceuticals — with management targeting roughly 51% revenue from new-age business by 2029, backed by product launches, a pet-focused acquisition and targeted state-by-state rollouts that are delivering higher gross margins for Fredun Pharmaceuticals.
Fredun Pharmaceuticals completed a QIP recently and cites the proceeds alongside improved internal cash flows to meet working capital; finance costs rose in the short term due to bank changes and machinery loans, but management expects the elevated finance cost to moderate over the next few quarters as QIP liquidity is deployed.
Operations combine owned plants (clusters of 3–4) and an asset-light CMO network of ~37 partner facilities, plus recent automation investments; seasonality persists with March quarter typically stronger, while mobility and pet volumetric products require different distribution and stocking strategies that Fredun Pharmaceuticals is scaling across states.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 1,274 Cr
Volatility: Low Risk
P/E Ratio: 34.0
Industry P/E: 34.1
PEG Ratio: 0.8
P/B Ratio: 4.5
52W High: 2,620.00
52W Low: 720.25

Sales CAGR

1Y: 30.35%
3Y: 26.45%
5Y: 32.11%
10Y: 30.16%

Profit CAGR

1Y: 33.23%
3Y: 48.65%
5Y: 61.36%
10Y: 39.07%

ROE

TTM: 11.73%
3Y: 13.15%
5Y: 11.82%
10Y: 11.33%

ROCE

TTM: 15.97%
3Y: 26.94%
5Y: 21.97%
10Y: 20.86%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
INDSWFTLAB		164.15	1,405 Cr	33.94	1.02	0.00	3.57	4.36	2.47
SYNCOMF		14.02	1,371 Cr	17.93	3.30	0.00	18.42	24.46	14.32
SHUKRAPHAR		31.20	1,348 Cr	61.12	15.00	0.00	24.55	31.50	18.78
JAGSNPHARM		205.40	1,324 Cr	30.72	4.80	2.02	15.60	20.59	13.60
LINCOLN		631.70	1,277 Cr	14.52	1.68	0.28	11.60	15.18	9.87
FREDUN		2325.00	1,274 Cr	34.01	4.50	0.03	11.73	15.97	5.83
ACCENTMIC		460.95	1,142 Cr	26.03	4.14	0.21	15.92	21.28	13.63
Median: 7 Co.	—	205.40	1,324 Cr	30.72	4.14	0.03	15.60	20.59	13.60

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Sep 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	0.00	167	120	145	161	213
Expenses	0.00	150	103	123	135	184
Operating Profit	0.00	17	17	22	26	29
OPM %	—	10.30	14.18	15.37	16.36	13.56
Other Income	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.00	8.15	6.53	7.73	11	14
Depreciation	0.00	1.84	1.42	1.89	1.78	3.15
Profit Before Tax	0.00	7.26	9.04	13	14	11
Tax %	—	17.36	25.11	25.73	25.14	4.18
Net Profit	0.00	6.00	6.77	9.43	10	11
EPS in Rs	0.00	10.97	12.36	17.24	21.76	18.22

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2025
Sales	454
Expenses	401
Operating Profit	52
OPM %	11.56
Other Income	2.45
Interest	22
Depreciation	5.04
Profit Before Tax	27
Tax %	28.20
Net Profit	20
EPS in Rs	—
Dividend Payout %	1.65

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2025
Equity Capital	4.72
Reserves	137
Borrowings	167
Other Liabilities	179
Total Liabilities	487
Fixed Assets	53
CWIP	0.00
Investments	1.50
Other Assets	433
Total Assets	487

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2025
Cash from Operating Activity	-29
Cash from Investing Activity	-6.35
Cash from Financing Activity	39
Net Cash Flow	3.70

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2023	Mar 2024	Apr 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Feb 2026	Mar 2026
Promoters	49.16%	49.17%	48.92%	49.17%	48.93%	48.93%	48.93%	48.93%	48.93%	43.06%	43.06%	44.17%
FIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.46%	1.06%	1.06%
DIIs	1.60%	1.60%	1.59%	1.60%	1.59%	1.59%	1.59%	1.59%	1.60%	3.48%	2.89%	2.83%
Public	49.25%	49.24%	49.49%	49.24%	49.48%	49.48%	49.48%	49.48%	49.45%	53.00%	52.99%	51.94%
Total Shareholders	6,837	7,507	6,840	7,511	8,018	8,121	7,976	7,906	8,120	8,765	8,443	8,400

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY23

Investor Presentation

Q4 FY19

Available on Pro Plan

Unlock reports, presentations, and AI-powered insights.

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Earnings Call

4 days ago

Fredun Pharmaceuticals Q4 FY26 Earnings Call

Fredun Pharmaceuticals will host its Q4 FY26 earnings conference call on Wednesday, 10 June 2026 at 11:00 AM IST; dial-in numbers and Diamond Pass registration link provided.

Earnings Call

4 days ago

Fredun Pharmaceuticals Q4 FY26 Earnings Conference Call on 10 Jun 2026

Company to host Q4 FY26 earnings conference call on 10 June 2026 at 11:00 AM IST; registration link and dial-in numbers provided for investor participation.

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Ltd (FREDUN) is currently trading at 2,325.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Fredun Pharmaceuticals Limited is an Indian diversified pharmaceutical company that develops, manufactures and markets generics, OTC, dermaceutics, nutraceuticals, pet-care products and mobility aids, operating both in-house plants and a network of contract manufacturing partners while supplying finished formulations to multiple international markets. Q3 FY26 total income rose to INR160.92 crore (+57% YoY) and 9M FY26 revenue reached INR426 crore (+48% YoY); EBITDA margins expanded meaningfully to ~15–16% with Q3 EBITDA of INR26.34 crore and net profit nearly doubling, reflecting simultaneous top-line growth and operational margin improvement across Fredun Pharmaceuticals' portfolio. The company is rapidly scaling its new-age verticals — pet care, mobility, dermaceutics and nutraceuticals — with management targeting roughly 51% revenue from new-age business by 2029, backed by product launches, a pet-focused acquisition and targeted state-by-state rollouts that are delivering higher gross margins for Fredun Pharmaceuticals. Fredun Pharmaceuticals completed a QIP recently and cites the proceeds alongside improved internal cash flows to meet working capital; finance costs rose in the short term due to bank changes and machinery loans, but management expects the elevated finance cost to moderate over the next few quarters as QIP liquidity is deployed. Operations combine owned plants (clusters of 3–4) and an asset-light CMO network of ~37 partner facilities, plus recent automation investments; seasonality persists with March quarter typically stronger, while mobility and pet volumetric products require different distribution and stocking strategies that Fredun Pharmaceuticals is scaling across states.

Over the past 52 weeks, Fredun Pharmaceuticals Ltd has traded between a low of ₹720.25 and a high of ₹2,620.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Fredun Pharmaceuticals Ltd has a market capitalization of approximately 1,274.12. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Fredun Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 34.01 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,274.12 Cr, Fredun Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Fredun Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Fredun Pharmaceuticals Ltd is 34.01. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Standalone net sales were Rs 159.93 crore for the quarter ended December 2025.

Fredun Pharmaceuticals Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison